We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
CNBC Stocks· Oct 29, 2026 · 5:44 PM
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
This is a summary. Read the complete story at CNBC Stocks below.
Read full article at CNBC Stocks
